perampanel

ApprovedTerminated

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Epilepsy

Conditions

Epilepsy

Trial Timeline

Nov 1, 2015 → Jul 1, 2017

NCT ID

NCT02727101

About perampanel

perampanel is a approved stage product being developed by Eisai for Epilepsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02727101. Target conditions include Epilepsy.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy were approved

Approved (20) Terminated (5) Active (0)

✅ZonegranEisaiApproved

✅Perampanel + PlaceboEisaiApproved

✅Perampanel Oral TabletEisaiApproved

✅PerampanelEisaiApproved

✅zonisamide low dose group + zonisamide high dose groupEisaiApproved

✅Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved

✅zonisamideEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01871233	Pre-clinical	Completed	—	—	Partial Onset Seizures
NCT02307578	Pre-clinical	Completed	—	—	Primary Generalized Tonic-Clonic or Partial Onset Seizures
NCT05533814	Approved	Completed	Oct 19, 2022	Jan 23, 2025	Epilepsy
NCT04252846	Pre-clinical	Completed	Jul 20, 2020	Jan 12, 2023	Idiopathic Generalized Epilepsy
NCT03836924	Pre-clinical	Completed	Feb 18, 2019	Mar 1, 2020	Partial Onset Seizures
NCT03424564	Phase 1	Completed	Mar 20, 2018	May 25, 2018	Healthy Subjects
NCT03288129	Approved	Completed	Aug 23, 2017	Apr 27, 2021	Partial Onset Seizures
NCT02914314	Phase 2	Completed	Feb 20, 2017	Apr 25, 2023	Epilepsy
NCT02849626	Phase 3	Completed	Nov 16, 2016	Dec 6, 2021	Partial-Onset or Primary Generalized Tonic-Clonic Seizures
NCT02726074	Approved	Completed	May 3, 2016	Apr 26, 2018	Epilepsy
NCT04230044	Pre-clinical	Completed	Apr 11, 2016	Jul 3, 2017	Epilepsy
NCT04257604	Pre-clinical	Completed	Jan 3, 2016	Apr 30, 2019	Partial Seizures
NCT02727101	Approved	Terminated	Nov 1, 2015	Jul 1, 2017	Epilepsy
NCT02427607	Phase 3	Completed	May 12, 2015	Nov 9, 2016	Epilepsy
NCT02279485	Phase 1	Completed	Sep 1, 2014	Jan 1, 2015	Healthy Subjects
NCT02033902	Pre-clinical	Completed	Jun 6, 2014	Jan 31, 2018	Epilepsy
NCT01527006	Phase 2	Completed	Jan 1, 2012	Apr 1, 2015	Central Nervous System
NCT00903786	Phase 2	Completed	Jun 17, 2009	Oct 31, 2016	Refractory Partial Seizures
NCT00735397	Phase 3	Completed	Oct 1, 2008	Sep 1, 2014	Epilepsy
NCT00505622	Phase 3	Terminated	Jul 1, 2007	Apr 1, 2008	Parkinson's Disease

Competing Products

20 competing products in Epilepsy

See all competitors

Product	Company	Stage	Hype Score
perampanel	Eisai	Phase 2	35
Lacosamide	UCB	Phase 3	40
Zonisamide + Placebo	Eisai	Phase 3	32
Zonegran	Eisai	Approved	35
perampanel + perampanel	Eisai	Phase 1	29
Perampanel + Placebo	Eisai	Approved	35
E2007 + Placebo	Eisai	Phase 2	35
Placebo + Rufinamide	Eisai	Phase 3	40
E2007 (perampanel) + Placebo	Eisai	Phase 2	35
Perampanel Oral Tablet	Eisai	Approved	43
perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Zonisamide + Carbamazepine	Eisai	Phase 3	40
Perampanel	Eisai	Approved	43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30	Eisai	Phase 1	29
Perampanel	Eisai	Phase 2	35
Zonisamide + Placebo	Eisai	Phase 3	40
zonisamide low dose group + zonisamide high dose group	Eisai	Approved	43
E2007 + E2007 + Placebo	Eisai	Phase 2	35
Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/day	Eisai	Approved	35